Skip to main content
Article thumbnail
Location of Repository

The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype

By Marielle WG Ruijs, Annegien Broeks, Fred H Menko, Margreet GEM Ausems, Anja Wagner, Rogier Oldenburg, Hanne Meijers-Heijboer, Laura J van't Veer and Senno Verhoef
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2664322
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2000). Absence of germline p16(INK4a) alterations in p53 wild type Li-Fraumeni syndrome families.
    2. (2004). AJ: A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell
    3. (2005). Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat
    4. (2004). CHEK2 is a multiorgan cancer susceptibility gene.
    5. (2001). CHK2 kinase – a busy messenger. Nat Rev Mol Cell Biol
    6. (2005). Dork T: Association of two mutations in the CHEK2 gene with breast cancer.
    7. (2002). Eeles RA: Increasing evidence that germline mutations in CHEK2 do not cause Li- Fraumeni syndrome. Hum Mutat
    8. (1969). Fraumeni JF Jr: Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med
    9. (2001). Frebourg T: Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome.
    10. (2008). Frebourg T: Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families.
    11. (2008). Garber JE: Time to check CHEK2 in families with breast cancer?
    12. (2004). Germ line BAX alterations are infrequent in Li-Fraumeni syndrome. Cancer Epidemiol Biomarkers Prev
    13. (1995). Germline mutations in the TP53 gene. Cancer Surv
    14. (2003). Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat
    15. (2001). Haber DA: Destabilization of CHK2 by a missense mutation associated with Li- Fraumeni Syndrome. Cancer Res
    16. (1999). Houlston RS: Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10. Cancer Lett
    17. (2000). Identification of a novel PTEN intronic deletion in Li-Fraumeni syndrome and its effect on RNA processing. Cancer Genet Cytogenet
    18. (1990). Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat
    19. (1999). JM: Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li- Fraumeni syndrome.
    20. (2006). King MC: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    21. (2003). Large Genomic Deletions and Duplications in the BRCA1 Gene Identified by a Novel Quantitative Method. Cancer Research
    22. (2002). MR: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet
    23. (2001). Mutation analysis of the CHK2 gene in families with hereditary breast cancer.
    24. (2004). N: Limited relevance of the CHEK2 gene in hereditary breast cancer.
    25. (2008). Narod SA: Is CHEK2 a cause of the Li-Fraumeni syndrome?
    26. (2002). Nevanlinna H: A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
    27. (2004). Nevanlinna H: CHEK2 variant I157T may be associated with increased breast cancer risk.
    28. (2001). Nevanlinna H: p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res
    29. (2008). Nordestgaard BG: CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    30. (2005). Offit K: The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam Cancer
    31. (2005). polymorphism on age of tumour onset in LiFraumeni syndrome.
    32. (2008). Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res
    33. (1988). RW: A cancer family syndrome in twenty-four kindreds. Cancer Res
    34. (1994). SantibanezKoref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res
    35. (1990). SH: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science
    36. (2004). The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
    37. (2003). The CHEK2 1100delC Mutation Identifies Families with a Hereditary Breast and Colorectal Cancer Phenotype.
    38. (2004). van't Veer LJ: Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers. Breast Cancer Res Treat
    39. (2007). Van't Veer LJ: The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.